Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1992-12-10
|
| pubmed:abstractText |
A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0898-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
78-81
|
| pubmed:dateRevised |
2007-7-23
|
| pubmed:meshHeading |
pubmed-meshheading:1428412-Antibodies, Monoclonal,
pubmed-meshheading:1428412-Antibody Formation,
pubmed-meshheading:1428412-Cytotoxicity, Immunologic,
pubmed-meshheading:1428412-Female,
pubmed-meshheading:1428412-Humans,
pubmed-meshheading:1428412-Immunotherapy, Adoptive,
pubmed-meshheading:1428412-Interleukin-2,
pubmed-meshheading:1428412-Lymphocyte Activation,
pubmed-meshheading:1428412-Ovarian Neoplasms,
pubmed-meshheading:1428412-T-Lymphocytes
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
|
| pubmed:affiliation |
Department of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|